Specific medical use formulae useful for enhancing and / or improving social behavior in individuals

Abstract

The present invention provides special medical use formulae useful for enhancing and / or improving the social behavior of an individual. The formula food for the special medical purpose comprises DHA (docosahexaenoic acid), ARA (arachidonic acid) and breast milk oligosaccharide 6-SL and / or LNnT, and the mass ratio of the DHA to the ARA to the breast milk oligosaccharide 6-SL and / or LNnT is (70-210): (60-420): (10-400). The special medical use formulae of the present invention contribute to enhancing and / or improving the social behavior of an individual.

Description

Technical Field

[0001] The present invention belongs to the technical field of special medical purpose formula foods, and specifically relates to a special medical purpose formula food and its application which helps to enhance and / or improve individual social behavior. Background Art

[0002] Social behavior refers to an individual's ability to interact with people around him or her and to take care of himself or herself. It is one of the attributes for assessing the developmental behavior level of children aged 0 to 6 years old (under 7 years old).

[0003] Food for Special Medical Purpose (FSMP) is a specially processed and prepared food to meet the special needs of people with restricted food intake, digestive and absorption disorders, metabolic disorders or specific disease states for nutrients or diets. FSMP includes special medical formula for infants aged 0 to 12 months and special medical formula for people over 1 year old.

[0004] After searching, there are few reports in the prior art on whether diet affects individual social behavior and what kind of impact it has on individual social behavior. Summary of the invention

[0005] An object of the present invention is to provide a special medical formula food that helps to greatly enhance and / or improve an individual's social behavior.

[0006] Another object of the present invention is to provide related applications of the special medical purpose formula food.

[0007] The present invention has found that polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and arachidonic acid (ARA), human milk oligosaccharides (such as 6-SL, LNnT, etc.) and their compositions (i.e., compositions comprising DHA, ARA and human milk oligosaccharides) can affect the social behavior of an individual. In particular, when DHA, ARA and human milk oligosaccharides (especially 6-SL and / or LNnT) are combined in a certain proportion, they have a synergistic effect on enhancing and / or improving the social behavior of an individual.

[0008] On the one hand, the present invention provides a special medical purpose formula food, which contains DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT, wherein the mass ratio of DHA, ARA to human milk oligosaccharides 6-SL and / or LNnT is (70-210): (60-420): (10-400).

[0009] According to a specific embodiment of the present invention, the special medical purpose formula food of the present invention is selected from one or more of the following: lactose-free formula or low-lactose formula food for infants, partially hydrolyzed formula food for infant milk protein, deeply hydrolyzed formula food for infant milk protein, infant amino acid formula food, formula food for premature / low birth weight infants, breast milk nutritional supplements, infant amino acid metabolism disorder formula food, food protein allergy complete nutrition formula food, inflammatory bowel disease complete nutrition formula food, gastrointestinal absorption disorder complete nutrition formula food, fatty acid metabolism abnormal complete nutrition formula food.

[0010] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is 0.2-5:1.

[0011] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is 0.3-3:1.

[0012] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1.

[0013] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1.

[0014] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0015] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210): (60-420): (40-400).

[0016] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210): (60-420): (80-400).

[0017] According to some specific embodiments of the present invention, the special medical purpose formula food comprises DHA, ARA and 6-SL.

[0018] According to some specific embodiments of the present invention, the special medical purpose formula food comprises DHA, ARA and LNnT.

[0019] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the raw material for providing the DHA can be a commercially available DHA raw material with higher purity, or it can be DHA oil and / or powder derived from one or a combination of two or more of algae, tuna oil, fish oil, milk-derived DHA from feed nutrition regulation and biotransformation, egg yolk extract and krill oil; wherein the algae can be one or a combination of two or more of Schizochytrium, Okenichytrium and Crypthecodinium. Unless otherwise specified, the ratio of DHA to other functional components in the special medical purpose formula food of the present invention is based on the content of DHA in the raw material.

[0020] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the raw material for providing the ARA can be a commercially available ARA raw material with higher purity, or it can be one or more raw materials derived from algae and other oils containing ARA. Unless otherwise specified, the ratio of the ARA to other functional components in the special medical purpose formula food of the present invention is based on the content of ARA in the raw material.

[0021] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the raw material for providing the human milk oligosaccharide 6-SL and / or LNnT can be a commercially available human milk oligosaccharide raw material with higher purity. Unless otherwise specified, the ratio of the human milk oligosaccharide 6-SL and / or LNnT to other functional components in the special medical purpose formula food of the present invention is based on the content of human milk oligosaccharide 6-SL and / or LNnT in the raw material. When the human milk oligosaccharide described in the special medical purpose formula food of the present invention is 6-SL and LNnT, its ratio with other functional components is based on the total content of 6-SL and LNnT in the raw material, wherein 6-SL and LNnT can be in any ratio.

[0022] According to a specific embodiment of the present invention, the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the special medical purpose formula food of the present invention is 10-400 mg / 100 g food dry matter.

[0023] According to a specific embodiment of the present invention, the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the special medical purpose formula food of the present invention is 80-300 mg / 100 g food dry matter.

[0024] In some specific embodiments of the present invention, the amount of human milk oligosaccharide 6-SL contained in the special medical purpose formula food of the present invention is 80-300 mg / 100 g food dry matter.

[0025] In some specific embodiments of the present invention, the amount of human milk oligosaccharide LNnT contained in the special medical purpose formula food of the present invention is 80-200 mg / 100 g food dry matter.

[0026] According to a specific embodiment of the present invention, the content of DHA and ARA in the special medical purpose formula food of the present invention can be determined according to the ratio with the human milk oligosaccharide 6-SL and / or LNnT.

[0027] According to a specific embodiment of the present invention, the special medical purpose formula food of the present invention preferably contains a total amount of DHA and ARA of 130-630 mg / 100 g of food dry matter.

[0028] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, based on the dry matter weight of the special medical purpose formula food, the protein content is 10-16g / 100g, the fat content is 10-32g / 100g, and the carbohydrate content is 50-58g / 100g.

[0029] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the protein can be plant protein and / or animal protein. In some specific embodiments of the present invention, the protein includes milk protein, preferably selected from cow milk protein and / or goat milk protein. In some specific embodiments of the present invention, the protein can be, for example, a protein derived from cow milk, including cow milk whole protein, specifically commercially available milk protein powder or whey protein powder. In some specific embodiments of the present invention, the whey protein content in the protein is not less than 40%, preferably not less than 60%. For special medical purpose infant formula food, the protein therein is preferably partially hydrolyzed or deeply hydrolyzed. For special medical purpose infant formula food, the total protein therein is preferably 0.45g-0.7g / 100kJ.

[0030] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the raw material for providing fat includes vegetable oil in addition to the basic raw material containing milk fat, and the vegetable oil may include but is not limited to one or more of sunflower oil, corn oil, soybean oil, rapeseed oil, coconut oil, palm oil, and walnut oil, preferably including sunflower oil, corn oil and soybean oil. The addition of these vegetable oils provides fat components for the product on the one hand, and linoleic acid and α-linolenic acid on the other hand. In addition, the raw material for providing fat may also selectively include medium-chain triglycerides, and raw material OPO structured fat added to provide 1,3-dioleyl-2-palmitoyl triglyceride. Since the purity of the OPO structural fat raw materials currently sold on the market is different, that is, the content of the effective ingredient 1,3-dioleyl-2-palmityl triglyceride is different, usually around 40% to 70%, in the present invention, in order to distinguish the effective ingredient 1,3-dioleyl-2-palmityl triglyceride and its raw materials, the term "1,3-dioleyl-2-palmityl triglyceride" is used when describing the effective ingredient, and the commonly known "OPO structural fat" is used when describing the food raw materials providing the effective ingredient 1,3-dioleyl-2-palmityl triglyceride. The specific addition amount of OPO structural fat can be converted according to the content requirements of 1,3-dioleyl-2-palmityl triglyceride in the milk powder product of the present invention and the purity of the OPO structural fat raw material. More preferably, based on 1000 parts by weight of the special medical formula food, its raw materials include but are not limited to: 0-150 parts by weight of sunflower oil; 0-50 parts by weight of corn oil; 0-80 parts by weight of soybean oil; 0-100 parts by weight of rapeseed oil; 0-150 parts by weight of medium-chain triglycerides; 0-140 parts by weight of OPO structured fat. For special medical infant formula food, the total fat therein is preferably 1.05g-1.40g / 100kJ.

[0031] According to a specific embodiment of the present invention, in the special medical formula food of the present invention, carbohydrates come from lactose or non-lactose sources, including but not limited to pregelatinized starch, maltodextrin, solid corn syrup, glucose syrup, and partly from modified starch emulsifiers. That is, in the formula powder of the present invention, the raw materials for providing carbohydrates include but are not limited to raw breast milk oligosaccharides, lactose, emulsifiers and pre-hydrolyzed or gelatinized starch substances in addition to the basic raw materials containing lactose. Preferably, based on 1000 parts by weight of the special medical formula food, its raw materials include but are not limited to: 0-580 parts by weight of lactose, 0-580 parts by weight of non-lactose substances. The specific amount of lactose added can be adjusted within the range so that the carbohydrate content in the special medical formula food of the present invention is 50-58g / 100g. For special medical infant formula food, the amount of carbohydrates therein should be 2.2g-3.3g / 100kJ.

[0032] According to a specific embodiment of the present invention, the raw materials of the special medical formula food of the present invention further include but are not limited to one or more of appropriate EPA, nucleotides, lactoferrin, etc., and also include compound nutrients including calcium powder, vitamins and minerals. Preferably, based on 1000 parts by weight of the special medical formula food, its raw materials include: EPA is 10-140 parts by weight; compound nutrients including calcium powder, vitamins and minerals are 7-60 parts by weight.

[0033] In the special medical purpose formula food of the present invention, the compound nutrients are a combination of nutrients that meet national standards, and different addition amounts are used according to different formulas. If nutrients are added to the special medical purpose formula food of the present invention as needed, any one or any combination of the following compound nutrient components can be selectively used.

[0034] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the compound nutrients at least include compound vitamins, calcium powder, and mineral nutrition packs, and the amount of each component is:

[0035] 1) Compound vitamins, per gram of compound vitamins:

[0036] Taurine: 25-340 mg

[0037] Vitamin A: 1700~5800μgRE

[0038] Vitamin D: 25-70 μg

[0039] Vitamin B1: 2000-6800 μg

[0040] Vitamin B2: 3000-6900 μg

[0041] Vitamin B6: 1700-4000 μg

[0042] Vitamin B 12 :8~20μg

[0043] Vitamin K1: 200-700 μg

[0044] Vitamin C: 0-700 mg

[0045] Vitamin E: 10-70 mg α-TE

[0046] Nicotinamide: 10000~41550μg

[0047] Folic acid: 350-920 μg

[0048] Biotin: 70-245 μg

[0049] Pantothenic acid: 7100-25230 μg

[0050] Inositol: 0-250mg

[0051] L-Carnitine: 0-60mg

[0052] 2) Mineral II, per gram of Mineral II:

[0053] Sodium: 40-100 mg

[0054] Potassium: 200-500 mg

[0055] 2) Mineral Three, each gram of Mineral Three:

[0056] Calcium: 200-500 mg

[0057] Phosphorus: 75-300 mg

[0058] 3) Minerals 1, minerals 1 per gram:

[0059] Iron: 20-110 mg

[0060] Zinc: 23-90 mg

[0061] Copper: 2000-4180 μg

[0062] Iodine: 500-995 μg

[0063] Selenium: 0-200 μg

[0064] Manganese: 0-579 μg

[0065] 4) Compound magnesium chloride, each gram of magnesium chloride contains:

[0066] Magnesium: 80-170 mg

[0067] 5) Choline chloride, each gram of choline chloride is packaged

[0068] Choline: 200-950 mg.

[0069] The base material of the above-mentioned compound nutrients is preferably lactose, solid corn syrup or L-sodium ascorbate. Based on 1000 parts by weight of the nutritional composition that helps to enhance and / or improve individual social behavior in special medical purpose formula food, the addition amount of compound nutrients is 7 to 70 parts by weight, wherein the compound vitamin nutrition package is preferably 2 to 8 parts by weight, the mineral second nutrition package is preferably 2 to 40 parts by weight, the mineral three nutrition package is preferably 0.5 to 40 parts by weight, the mineral one nutrition package is preferably 0.5 to 6 parts by weight, magnesium chloride is 0 to 7 parts by weight, choline chloride is 0 to 3 parts by weight, and the base material of each nutrition package is preferably maltodextrin or L-sodium ascorbate.

[0070] The content of each component of the above-mentioned compound nutrients refers to the amount added to strengthen the nutrient substance, and does not include the content of nutrient components in other raw materials of milk powder.

[0071] It is understandable that for different types of special medical purpose formula foods, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0072] In some specific embodiments of the present invention, the formula food for special medical purposes of the present invention is a partially hydrolyzed formula food for infant milk protein, wherein the total protein includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 30% of the total protein, preferably more than 40%; based on 1000 parts by weight of the partially hydrolyzed formula food for infant milk protein, its raw materials include:

[0073]

[0074] In some specific embodiments of the present invention, the formula food for special medical purposes of the present invention is an infant milk protein deeply hydrolyzed formula food, wherein the total protein includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 70% of the total protein, preferably more than 80%; based on 1000 parts by weight of the infant milk protein deeply hydrolyzed formula food, its raw materials include:

[0075]

[0076]

[0077] It is understood that the specific amount of each raw material in the special medical purpose formula food of the present invention, such as the partially hydrolyzed formula food of infant milk protein or the deeply hydrolyzed formula food of infant milk protein, should be adjusted and determined under the premise of meeting the requirements of the formula milk powder product index. In the partially hydrolyzed formula food of infant milk protein or the deeply hydrolyzed formula food of infant milk protein of the present invention, the product performance indexes not described or listed in detail should be implemented in accordance with the national standards of the partially hydrolyzed formula food of infant milk protein or the deeply hydrolyzed formula food of infant milk protein and the provisions of relevant standards and regulations.

[0078] In the infant milk protein partially hydrolyzed formula food or the infant milk protein deeply hydrolyzed formula food of the present invention, each raw material can be commercially available, and the selection of each raw material should meet the requirements of relevant standards. In addition, the compounded nutrients can also be compounded by themselves. In the present invention, "compounding" is only used for the convenience of expression, which does not mean that each component in the compound must be mixed together before application. Each raw material should be added and used under the premise of meeting relevant laws and regulations.

[0079] On the other hand, the present invention also provides the use of a composition comprising DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT in the preparation of a special medical formula food that helps to enhance and / or improve the social behavior of an individual. The special medical formula food is any of the foregoing embodiments of the present invention.

[0080] The present invention also provides the use of the special medical formula food described in item 1 in preparing a product that helps to enhance and / or improve the social behavior of an individual. The product can be the special medical formula food of any of the aforementioned schemes of the present invention, or can be other products further prepared based on the special medical formula food of the present invention.

[0081] According to some specific embodiments of the present invention, the functional components in the special medical purpose formula food are composed of DHA, ARA and human milk oligosaccharide 6-SL and / or LNnT, and the proportion of each component can be any of the above proportions of the present invention. The efficacy refers to enhancing and / or improving the social behavior of an individual.

[0082] According to a specific embodiment of the present invention, in the present invention, the enhancing and / or improving the social behavior of an individual includes: enhancing the social willingness and / or social ability of an individual.

[0083] According to a specific embodiment of the present invention, in the present invention, the social ability includes social adaptability (the ability of an individual to respond to and adapt to the social environment and / or social needs around him / her).

[0084] According to a specific embodiment of the present invention, the special medical purpose formula food of the present invention is used in the preparation of a product that helps to enhance and / or improve the social behavior of an individual, wherein the individual is an infant, a toddler or a child. The special medical purpose formula food of the present invention can improve the low social behavior ability of an individual.

[0085] In the present invention, unless otherwise specified, the infant refers to an infant of 0-12 months, the toddler refers to an infant of 1-3 years old, and the child refers to a minor, particularly a child of 0 to 6 years old (under 7 years old).

[0086] The special medical purpose formula food provided by the present invention comprises polyunsaturated fatty acids DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT, which are helpful to enhance and / or improve the social behavior of an individual, and these functional components have a certain synergistic effect in enhancing and / or improving the social behavior of an individual. BRIEF DESCRIPTION OF THE DRAWINGS

[0087] Figure 1 The results of the approach cumulative time test for the 1:1 DHA and ARA combination experimental group are shown.

[0088] Figure 2 The detection results show the approaching frequency of the experimental group of 1:1 DHA and ARA combination.

[0089] Figure 3 The test results of the cumulative body contact time of the 1:1 DHA and ARA combination experimental group are shown.

[0090] Figure 4 The results of the body contact frequency test for the 1:1 DHA and ARA combination experimental group are shown.

[0091] Figure 5 The results of the relative movement accumulation time test of the 1:1 DHA and ARA combination experimental group are shown.

[0092] Figure 6 The results of the relative movement frequency test of the 1:1 DHA and ARA combination experimental group are shown.

[0093] Figure 7 The test results of the approach cumulative time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0094] Figure 8 The results of the detection of the approaching frequencies of the experimental groups of the compositions of DHA and ARA at different ratios are shown.

[0095] Fig. 9 The test results of the cumulative body contact time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0096] Fig.10 The results of the body contact frequency test of the experimental groups of different ratios of DHA and ARA compositions are shown.

[0097] Fig.11 The test results of the relative movement cumulative time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0098] Fig.12 The results of the relative movement frequency test of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0099] Fig.13 The results of the test showing the cumulative time of convergence for different HMO experimental groups.

[0100] Fig.14 Results showing the detection of convergence frequencies of different HMO experimental groups.

[0101] Fig.15 Results showing the cumulative duration of physical contact for the different HMO experimental groups.

[0102] Fig.16 Results showing the frequency of physical contact for different HMO experimental groups.

[0103] Fig.17 The results of the relative movement accumulation time test of different HMO experimental groups are shown.

[0104] Fig.18 Results showing the relative movement frequencies of different HMO experimental groups.

[0105] Fig.19 The test results showing the approach cumulative time for the DHA+ARA+HMO experimental group.

[0106] Fig. 20 The results of the detection of the approaching frequency of the DHA+ARA+HMO experimental group are shown.

[0107] Fig.21 The test results showing the cumulative time of body contact for the DHA+ARA+HMO experimental group.

[0108] Fig. 22 The test results showing the frequency of physical contact for the DHA+ARA+HMO experimental group.

[0109] Fig.23 The test results of the relative movement cumulative time of the DHA+ARA+HMO experimental group are displayed.

[0110] Fig.24 The results of the relative movement frequency test of the DHA+ARA+HMO experimental group are shown. DETAILED DESCRIPTION

[0111] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0112] When numerical ranges are given in the embodiments, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected unless otherwise specified in the present invention.

[0113] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0114] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0115] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0116] In each embodiment and experiment, the DHA, ARA and HMO used are all commercially available food grade raw materials. Unless otherwise specified, the DHA, ARA and HMO mentioned in the present invention are all calculated based on the effective content of the functional components DHA, ARA and HMO in the raw materials.

[0117] Example 1

[0118] Partially hydrolyzed infant milk protein formula containing a nutritional composition that helps to enhance and / or improve the social behavior of an individual:

[0119] 155 kg of hydrolyzed whey protein powder, 270 kg of lactose, 270 kg of solid corn syrup, 115 kg of high oleic sunflower oil, 85 kg of soybean oil, 80 kg of OPO structured fat, 38 kg of complex nutrients, 3 kg of DHA, 7 kg of ARA, 1 kg of LNnt, 1 kg of 6-SL, 0.1 kg of bifidobacterium, and 0.65 kg of nucleotides.

[0120] The compound nutrients include about 3.0 kg of compound vitamin nutrient package, about 2.0 kg of choline chloride nutrient package, about 12 kg of calcium powder nutrient package, 16 kg of sodium-potassium nutrient package, about 2 kg of mineral nutrient package, and about 3.0 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0121] The product contains 13.5g / 100g of protein, 28g / 100g of fat, 54g / 100g of carbohydrates, 100mg / 100g of DHA, 220mg / 100g of ARA, and 200mg / 100g of LNnt and 6-SL. The ratio of DHA to ARA is 0.45:1; the ratio of DHA to ARA to human milk oligosaccharides 6-SL and / or LNnT is 100:220:200.

[0122] The preparation process of the partially hydrolyzed infant milk protein formula food containing the nutritional composition that helps to enhance and / or improve the social behavior of an individual is as follows:

[0123] 1) Powder addition: Various powder raw materials are measured according to the formula and added into the powder mixing tank through the air delivery system for storage.

[0124] 2) Vacuum powder suction: Various powder raw materials in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system.

[0125] 3) Melting and oil preparation: Put the grease specified in the formula into the carburettor room according to the formula requirements. The temperature in the carburettor room should be maintained at 50-90°C. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements.

[0126] 4) Storage of mixed oil: The mixed oil is stored in an oil storage tank at a temperature of 40-50°C and the storage time is less than 12 hours to prevent fat oxidation.

[0127] 5) Weighing: Pump the mixed oil into the mixing tank through the oil pump according to the formula requirements.

[0128] 6) Dissolved and added nutrients: Calcium powder, minerals, vitamins, etc. are added separately with 100-200 kg of pure water. After dissolving them separately, they are pumped into the wet mixing tank. After each one is added, rinse the addition tank and pipeline with 100 kg of pure water.

[0129] 7) Filtration: The mixed liquid is filtered through a filter to remove physical impurities that may be introduced into the raw materials.

[0130] 8) Homogenization: The mixed liquid is homogenized by a homogenizer. The first-stage pressure is 105±5 bar and the second-stage pressure is 32±3 bar. The fat globules are mechanically treated and dispersed into uniform fat globules.

[0131] 9) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: it is cooled to below 20°C and temporarily stored in the pre-storage tank. It enters the next process within 6 hours, and the agitator is turned on according to the set requirements.

[0132] 10) Concentration and sterilization: Double-effect concentration is used during production, the sterilization temperature is ≥83°C, and the sterilization time is 25 seconds. The discharge concentration is 48% to 52% dry matter.

[0133] 11) Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank. It is preheated to 60-70℃ by the scraper preheater. After preheating, the material is filtered through a filter with a pore size of 1mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. Inlet air temperature: 165-180℃, exhaust air temperature 75-90℃, high-pressure pump pressure 160-210bar, tower negative pressure -4 to -2mbar.

[0134] 12) Fluidized bed drying and cooling: The powder coming out of the drying tower is dried again in a fluidized bed (primary) and then cooled to 25-30°C in a fluidized bed (secondary). At the same time, human milk oligosaccharide is mixed with the carrier and heated to 60-65°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder, so that the powder particles agglomerate to increase its particle size and solubility.

[0135] 13) Packaging: The flour-making workshop staff weighs and seals the DHA, ARA, nucleotides and bifidobacteria in accordance with the formula requirements.

[0136] 14) Dry mixing: Mix the weighed DHA, ARA, LNnt, 6-SL, nucleotides, bifidobacteria and milk powder in a dry mixer.

[0137] 15) Powder screening: Use a vibrating screen to make the particle size of the milk powder uniform and discard the powder residue.

[0138] 16) Powder output: Collect the powder in a sterilized powder box and transport it from the powder output room to the powder loading room.

[0139] 17) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0140] 18) Packaging: 800g automatic packaging machine nitrogen filling packaging. The oxygen content during nitrogen filling is less than 1%. 900g iron cans automatically filled with nitrogen packaging oxygen content less than 5%.

[0141] 19) Packing: Put the packaged sachets into cartons and add the powder spoon, then seal with a carton sealing machine.

[0142] 20) Finished product inspection: Sampling inspection is carried out on the packaged products according to the inspection plan.

[0143] 21) Storage: Products that have passed the inspection shall be stored in warehouses at room temperature with humidity ≤ 65%.

[0144] Example 2

[0145] Partially hydrolyzed infant milk protein formula containing a nutritional composition that helps to enhance and / or improve the social behavior of an individual:

[0146] 160 kg of hydrolyzed whey protein powder, 270 kg of lactose, 270 kg of solid corn syrup, 80 kg of high oleic sunflower oil, 90 kg of soybean oil, 90 kg of OPO structured fat, 38 kg of complex nutrients, 5.5 kg of DHA, 6.5 kg of ARA, 0.5 kg of LNnt, 2 kg of 6-SL, 0.1 kg of bifidobacterium, and 0.65 kg of nucleotides.

[0147] The compound nutrients include about 3.0 kg of compound vitamin nutrient package, about 2.0 kg of choline chloride nutrient package, about 12 kg of calcium powder nutrient package, 16 kg of sodium-potassium nutrient package, about 2 kg of mineral nutrient package, and about 3.0 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0148] The product contains 14g / 100g protein, 26g / 100g fat, 54g / 100g carbohydrate, 180mg / 100g DHA, 190mg / 100g ARA, 250mg / 100g LNnt and 6-SL. The ratio of DHA to ARA is 0.95:1; the ratio of DHA to ARA to human milk oligosaccharides 6-SL and / or LNnT is 180:190:250.

[0149] Example 3

[0150] Infant milk protein extensively hydrolyzed formula containing a nutritional composition that helps to enhance and / or improve an individual's social behavior:

[0151] 175 kg of hydrolyzed whey protein powder, 500 kg of maltodextrin, 60 kg of soybean oil, 160 kg of medium-chain triglycerides, 50 kg of OPO structured fat, 55 kg of complex nutrients, 6.5 kg of DHA, 13 kg of ARA, 0.5 kg of LNnt, 0.5 kg of 6-SL, and 0.3 kg of nucleotides.

[0152] The compound nutrients include about 4 kg of compound vitamin nutrient package, about 4 kg of choline chloride nutrient package, about 20 kg of calcium powder nutrient package, 19 kg of sodium-potassium nutrient package, about 4 kg of mineral nutrient package, and about 4 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0153] The product contains 15.3g / 100g of protein, 27g / 100g of fat, 50g / 100g of carbohydrates, 200mg / 100g of DHA, 400mg / 100g of ARA, and 100mg / 100g of LNnt and 6-SL. The ratio of DHA to ARA is 0.5:1; the ratio of DHA, ARA to human milk oligosaccharides 6-SL and / or LNnT is 200:400:100.

[0154] The preparation process of the infant milk protein extensively hydrolyzed formula food containing the nutritional composition that helps to enhance and / or improve the social behavior of an individual is as follows:

[0155] 1) Powder addition: Various powder raw materials are measured according to the formula and added into the powder mixing tank through the air delivery system for storage.

[0156] 2) Vacuum powder suction: Various powder raw materials in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system.

[0157] 3) Melting and oil preparation: Put the grease specified in the formula into the carburettor room according to the formula requirements. The temperature in the carburettor room should be maintained at 50-90°C. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements.

[0158] 4) Storage of mixed oil: The mixed oil is stored in an oil storage tank at a temperature of 40-50°C and the storage time is less than 12 hours to prevent fat oxidation.

[0159] 5) Weighing: Pump the mixed oil into the mixing tank through the oil pump according to the formula requirements.

[0160] 6) Dissolved and added nutrients: Calcium powder, minerals, vitamins, etc. are added separately with 100-200 kg of pure water. After dissolving them separately, they are pumped into the wet mixing tank. After each one is added, rinse the addition tank and pipeline with 100 kg of pure water.

[0161] 7) Filtration: The mixed liquid is filtered through a filter to remove physical impurities that may be introduced into the raw materials.

[0162] 8) Homogenization: The mixed liquid is homogenized by a homogenizer. The first-stage pressure is 105±5 bar and the second-stage pressure is 32±3 bar. The fat globules are mechanically treated and dispersed into uniform fat globules.

[0163] 9) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: it is cooled to below 20°C and temporarily stored in the pre-storage tank. It enters the next process within 6 hours, and the agitator is turned on according to the set requirements.

[0164] 10) Concentration and sterilization: Double-effect concentration is used during production, the sterilization temperature is ≥83°C, and the sterilization time is 25 seconds. The discharge concentration is 48% to 52% dry matter.

[0165] 11) Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank. It is preheated to 60-70℃ by the scraper preheater. After preheating, the material is filtered through a filter with a pore size of 1mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. Inlet air temperature: 165-180℃, exhaust air temperature 75-90℃, high-pressure pump pressure 160-210bar, tower negative pressure -4 to -2mbar.

[0166] 12) Fluidized bed drying and cooling: The powder coming out of the drying tower is dried again in a fluidized bed (primary) and then cooled to 25-30°C in a fluidized bed (secondary). At the same time, human milk oligosaccharide is mixed with the carrier and heated to 60-65°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder, so that the powder particles agglomerate to increase its particle size and solubility.

[0167] 13) Packaging: The flour-making workshop staff weighs and seals the DHA, ARA, nucleotides and bifidobacteria in accordance with the formula requirements.

[0168] 14) Dry mixing: Mix the weighed DHA, ARA, LNnt, 6-SL, nucleotides and milk powder in a dry mixer.

[0169] 15) Powder screening: Use a vibrating screen to make the particle size of the milk powder uniform and discard the powder residue.

[0170] 16) Powder output: Collect the powder in a sterilized powder box and transport it from the powder output room to the powder loading room.

[0171] 17) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0172] 18) Packaging: 800g automatic packaging machine nitrogen filling packaging. The oxygen content during nitrogen filling is less than 1%. 900g iron cans automatically filled with nitrogen packaging oxygen content less than 5%.

[0173] 19) Packing: Put the packaged sachets into cartons and add the powder spoon, then seal with a carton sealing machine.

[0174] 20) Finished product inspection: Sampling inspection is carried out on the packaged products according to the inspection plan.

[0175] 21) Storage: Products that have passed the inspection shall be stored in warehouses at room temperature with humidity ≤ 65%.

[0176] Example 4

[0177] Infant milk protein extensively hydrolyzed formula containing a nutritional composition that helps to enhance and / or improve an individual's social behavior:

[0178] 175 kg of hydrolyzed whey protein powder, 330 kg of maltodextrin, 210 kg of glucose syrup, 60 kg of soybean oil, 60 kg of sunflower oil, 90 kg of medium-chain triglycerides, 40 kg of OPO structured fat, 55 kg of complex nutrients, 3.5 kg of DHA, 6 kg of ARA, 2 kg of LNnt, 2 kg of 6-SL, and 0.4 kg of nucleotides.

[0179] The compound nutrients include about 4 kg of compound vitamin nutrient package, about 4 kg of choline chloride nutrient package, about 20 kg of calcium powder nutrient package, 19 kg of sodium-potassium nutrient package, about 4 kg of mineral nutrient package, and about 4 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0180] The product contains 15.3g / 100g of protein, 25g / 100g of fat, 54g / 100g of carbohydrates, 120mg / 100g of DHA, 180mg / 100g of ARA, and 400mg / 100g of LNnt and 6-SL. The ratio of DHA to ARA is 0.67:1; the ratio of DHA to ARA to human milk oligosaccharides 6-SL and / or LNnT is 120:180:400.

[0181] Experimental study on the efficacy of nutritional composition in improving individual social ability

[0182] 1. Bee species and grouping

[0183] One-day-old Italian honey bees (Apis mellifera) were used, and the intervention methods of different experimental groups were shown in Table 1 based on the diet of feed honey bees.

[0184] Table 1

[0185]

[0186] 2. Basic honey bee training

[0187] Preparation of diet for the CV group: Weigh 500 g of sucrose and 10 g of casein hydrolysate, dilute to 1 L with ultrapure water, stir to dissolve, filter and sterilize with a 0.22 μm filter membrane to obtain the 50% (w / v) sucrose solution containing 1% (w / v) casein hydrolysate required for the experiment.

[0188] Diet of treatment groups: The free-feeding group was given the treatment reagent on the basis of the CV diet; the single-fed group was given a daily diet of 40ul sugar water per bee, and the reagent was concentrated to 5ul sterile sugar water and gavage at one time.

[0189] Select honeycombs of appropriate age from the apiary, quickly transport them back to the laboratory, and place them in an incubator at 35°C and 60-80% humidity. Observe the status of the fledged bees every day from the second day (if they have not fledged, continue to culture), gently remove the fledged bees with tweezers and pack them into disposable transparent culture cups, 30 per cup, and pack enough cups according to the experimental needs.

[0190] The fledged bees were taken directly from the apiary, and the intestines were extracted. After adding 100ul PBS to each intestine and grinding, 50% glycerol was added in a 1:1 ratio and stored at -80°C.

[0191] Take a sterile 2mL centrifuge tube, add 990μL sterile PBS, add 10μL worker bee intestinal fluid, mix well, and finally use 50% (w / v) sterile sucrose solution to make up to 2mL mark, shake and mix well. Feed each cup of newly emerged bees with 1 tube of the above mixed solution and continue to culture in a constant temperature incubator for 24h.

[0192] After the colonization of intestinal fluid was completed, treatment feeding began. The CV group was fed with the CV diet, and the treatment group was fed with the treatment diet. Treatment feeding continued for 7 days. During this period, the growth status of the bees was observed daily and the diet was changed in time to ensure that the diet was sufficient. The culture conditions were: dark, 35℃, 60%-80% humidity.

[0193] Note: If the animal is gavage-fed individually, the diet placed in the feeding cup is CV diet, and only different treatment reagents are added to the gavage-fed diet.

[0194] 3. Experimental testing

[0195] Social behavior testing:

[0196] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0197] (2) Place the experimental bees in groups of three in a transparent, breathable open field that has been prepared in advance.

[0198] (3) The open field was acclimated on the experimental table for 15 minutes, and the open field was filmed from above for 45 minutes.

[0199] (4) The above video was analyzed using the Etho Vision XT 17 animal behavior analysis system to obtain the social behavior ability data of honey bees.

[0200] 4. Experimental Results

[0201] The present invention analyzes the effect of DHA and ARA in a ratio of 1:1 on individual social behavior. Figures 1 to 6 The results showed that in terms of individual social behavior, compared with the conventional diet, the DHA and ARA in a ratio of 1:1 significantly improved the approach frequency, cumulative approach time, physical contact frequency, cumulative physical contact time, relative movement frequency, and cumulative relative movement time. This shows that the addition of DHA and ARA combination will enhance individual social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that the DHA and ARA combination has an active role in promoting cognitive development.

[0202] The present invention also analyzes the effects of different ratios of DHA and ARA on social behavior. The results are as follows: Figures 7 to 12 As shown, bees fed a diet with a 1:1 ratio of DHA and ARA showed a significant trend in the frequency of physical contact, cumulative physical contact time, relative movement frequency, cumulative relative movement time, and cumulative approach time in the social behavior experiment compared with other groups. Bees fed a diet with a 1:1.5 and 1:2 ratio of DHA and ARA showed no significant trend in the detection of social behavior experimental indicators. Therefore, a DHA:ARA ratio of 1:1 was used in subsequent experiments for further verification.

[0203] The present invention also analyzed the effects of sialic acid HMO (i.e. 6-SL) and neutral sialic acid HMO (i.e. LNnT) on individual social behavior. Figures 13 to 18As shown, the HMO-added groups, especially the 6-SL group, showed a significant trend in approach frequency, physical contact frequency, relative movement frequency, and cumulative approach time in the social behavior experiment compared with other groups. This shows that adding HMO, especially sialic acid HMO, will enhance individual social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that HMO has an effect in promoting cognitive development.

[0204] The present invention also analyzes the effect of DHA+ARA+HMO composition on social behavior. Figure 19-Figure 24 As shown in the results, compared with the DHA and ARA group with a ratio of 1:1, and the 6-SL and LNnT group, the DHA+ARA+6-SL and nDHA+ARA+LNnT groups showed obvious trends in the cumulative approach time, approach frequency, cumulative physical contact time, relative movement frequency, and cumulative relative movement time in the social behavior experiment. This shows that the DHA+ARA+6-SL / LNnT composition has a synergistic function in improving social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that the composition has a synergistic function in promoting cognitive development.

[0205] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A special medical purpose formula food, comprising DHA, ARA and human milk oligosaccharide 6-SL and / or LNnT, wherein: The mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210):(60-420):(10-400); The special medical purpose formula food is selected from one or more of the following: lactose-free formula or low-lactose formula food for infants, partially hydrolyzed milk protein formula food for infants, deeply hydrolyzed milk protein formula food for infants, amino acid formula food for infants with premature / low birth weight, breast milk nutritional supplement, formula food for infants with amino acid metabolism disorders, complete nutritional formula food for food protein allergy, complete nutritional formula food for inflammatory bowel disease, complete nutritional formula food for gastrointestinal absorption disorders, and complete nutritional formula food for abnormal fatty acid metabolism.

2. The special medical purpose formula food according to claim 1, wherein: The mass ratio of DHA to ARA is 0.2-5:1, preferably 0.3-3:1, and more preferably 0.5-2.5:

1.

3. The special medical purpose formula food according to claim 1 or 2, wherein: The mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210):(60-420):(40-400); Preferably, the mass ratio of DHA, ARA to human milk oligosaccharides 6-SL and / or LNnT is (70-210): (60-420): (80-400).

4. The special medical purpose formula food according to any one of claims 1 to 3, wherein the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the food is 10-400 mg / 100 g of food dry matter; Preferably, the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the food is 80-300 mg / 100 g of food dry matter.

5. The special medical purpose formula food according to any one of claims 1 to 4, wherein: Calculated on the dry weight of the food for special medical purposes, the protein content is 10-16 g / 100 g, the fat content is 21-32 g / 100 g, and the carbohydrate content is 50-58 g / 100 g.

6. The special medical purpose formula food according to any one of claims 1 to 5, which is a partially hydrolyzed infant milk protein formula food, wherein the total protein includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 30% of the total protein, preferably more than 40%; based on 1000 parts by weight of the partially hydrolyzed infant milk protein formula food, its raw materials include:

7. The special medical purpose formula food according to any one of claims 1 to 5, which is an infant milk protein deep hydrolyzed formula food, wherein the total protein includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 70% of the total protein, preferably more than 80%; based on 1000 parts by weight of the infant milk protein partially hydrolyzed formula food, its raw materials include:

8. Use of the special medical purpose formula food according to any one of claims 1 to 7 in the preparation of a product that helps to enhance and / or improve the social behavior of an individual.

9. The use according to claim 8, wherein: The said enhancing and / or improving individual social behavior includes: enhancing individual social willingness and / or social ability; Preferably, the social ability includes social interaction ability and / or social adaptability.

10. The use according to claim 8 or 9, wherein: The individual is an infant, toddler or child.

Images